A better understanding of the mechanistic details of how TGF-β switches from a tumor suppressor to a pro-tumorigenic signal during hepatocarcinogenesis and the identification of biomarkers that would help better stratify patient selection may foster the clinical development of more effective TGF-β antagonists and improve patient responses to combination therapies. The gene discussed is TGFB1; the disease is neoplasm.